ISpecimen Ownership
| ISPC Stock | USD 1.08 0.00 0.00% |
Shares in Circulation | First Issued 2019-09-30 | Previous Quarter 1.7 M | Current Value 710.9 K | Avarage Shares Outstanding 383.9 K | Quarterly Volatility 362 K |
ISpecimen | Build AI portfolio with ISpecimen Stock |
ISpecimen Stock Ownership Analysis
The company has price-to-book (P/B) ratio of 1.61. Some equities with similar Price to Book (P/B) outperform the market in the long run. iSpecimen recorded a loss per share of 11.93. The entity had not issued any dividends in recent years. The firm had 1:20 split on the 16th of September 2024. iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. The company was incorporated in 2009 and is headquartered in Lexington, Massachusetts. Ispecimen operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 59 people. To learn more about iSpecimen call Robert Lim at 781 301 6700 or check out https://ispecimen.com.ISpecimen Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as ISpecimen is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading iSpecimen backward and forwards among themselves. ISpecimen's institutional investor refers to the entity that pools money to purchase ISpecimen's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bridgeway Capital Management, Llc | 2025-03-31 | 21.8 K | Ubs Group Ag | 2025-03-31 | 21.7 K | Geode Capital Management, Llc | 2025-03-31 | 10.7 K | Tower Research Capital Llc | 2025-03-31 | 3 K | Blackrock Inc | 2025-03-31 | 2.8 K | Bank Of America Corp | 2025-03-31 | 7.0 | Sbi Securities Co Ltd | 2025-03-31 | 2.0 | Sachetta Llc | 2025-03-31 | 2.0 | Fny Investment Advisers, Llc | 2024-12-31 | 0.0 | Jane Street Group Llc | 2024-12-31 | 0.0 |
iSpecimen Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ISpecimen insiders, such as employees or executives, is commonly permitted as long as it does not rely on ISpecimen's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ISpecimen insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
ISpecimen Outstanding Bonds
ISpecimen issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. iSpecimen uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most ISpecimen bonds can be classified according to their maturity, which is the date when iSpecimen has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether iSpecimen offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ISpecimen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ispecimen Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ispecimen Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in iSpecimen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade ISpecimen Stock refer to our How to Trade ISpecimen Stock guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ISpecimen. If investors know ISpecimen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ISpecimen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.93) | Revenue Per Share | Quarterly Revenue Growth (0.54) | Return On Assets | Return On Equity |
The market value of iSpecimen is measured differently than its book value, which is the value of ISpecimen that is recorded on the company's balance sheet. Investors also form their own opinion of ISpecimen's value that differs from its market value or its book value, called intrinsic value, which is ISpecimen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ISpecimen's market value can be influenced by many factors that don't directly affect ISpecimen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ISpecimen's value and its price as these two are different measures arrived at by different means. Investors typically determine if ISpecimen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ISpecimen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.